Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions

Expert Reviews in Molecular Medicine
Thomas W Geisbert, Lisa E Hensley

Abstract

Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicized isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90% in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current...Continue Reading

Citations

Jan 26, 2011·Immunology and Cell Biology·Lawrence W LeungChristopher F Basler
Dec 6, 2007·The Journal of Infectious Diseases·Mike Bray, Frederick A Murphy
Dec 6, 2007·The Journal of Infectious Diseases·Hideki EbiharaHeinz Feldmann
Dec 6, 2007·The Journal of Infectious Diseases·Allison GrosethHeinz Feldmann
Aug 22, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Christopher F Basler, Gaya K Amarasinghe
Nov 15, 2011·The Journal of Infectious Diseases·Annika KühlStefan Pöhlmann
Feb 19, 2009·Antimicrobial Agents and Chemotherapy·Dana L SwensonSina Bavari
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Sven EnterleinElke Mühlberger
Mar 12, 2010·Journal of Virology·Keita MatsunoAyato Takada
Jan 25, 2013·Journal of Virology·Osvaldo MartinezChristopher F Basler
Jan 10, 2009·Disease Models & Mechanisms·Dennis BenteHeinz Feldmann
Jul 20, 2006·PLoS Pathogens·Hideki EbiharaYoshihiro Kawaoka
Jan 24, 2007·PLoS Pathogens·Heinz FeldmannThomas W Geisbert
Jan 1, 2012·Uirusu·Ayato Takada
Dec 4, 2012·Viruses·Donna L PerryGary L White
Jun 7, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Robert M Krug
Jun 16, 2010·Proceedings of the National Academy of Sciences of the United States of America·Dana WillnerMatthew Haynes
Oct 18, 2013·Journal of Virology·Junki MaruyamaAyato Takada
Aug 23, 2011·Journal of Pharmaceutical Sciences·Lei HuC Russell Middaugh
Feb 16, 2012·Antiviral Research·Osvaldo MartinezChristopher F Basler
Jul 4, 2006·Clinics in Laboratory Medicine·Aileen M MartyThomas W Geisbert
Mar 27, 2007·Cellular Microbiology·Claudette L FullerSina Bavari
Oct 24, 2006·Vaccine·Ayato TakadaYoshihiro Kawaoka
Sep 20, 2005·Critical Care Clinics·David C Pigott
Jul 26, 2015·The Journal of Infectious Diseases·Lindsay Hill-BatorskiYoshihiro Kawaoka
Apr 20, 2010·Journal of Molecular Biology·Daisy W LeungGaya K Amarasinghe
Dec 24, 2010·Virulence·Daisy W LeungGaya K Amarasinghe
Nov 9, 2010·Biochemical and Biophysical Research Communications·Keita MatsunoAyato Takada
Dec 3, 2014·Biochemical and Biophysical Research Communications·Makoto KurodaAyato Takada
Apr 3, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D Falzaran, D A Bente
Dec 21, 2012·The Journal of Infectious Diseases·Lauren M SmithChristopher L Karp
Dec 22, 2006·Expert Review of Anti-infective Therapy·Mike Bray, Richard Pilch
Apr 20, 2014·Expert Review of Clinical Immunology·Gary WongXiangguo Qiu
Oct 19, 2011·The Journal of Infectious Diseases·Glenn A MarshDeborah Middleton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.